Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Haim Bitterman"'
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138229 (2015)
The relative efficacy of lapatinib vs. continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic breast cancer (MBC) patients, who progressed on first-line trastuzumab, is still unclear. The objective of this population based cohort
Externí odkaz:
https://doaj.org/article/38a8ad1c73f7441a93645abff5274214
Autor:
Becca S Feldman, Chandra J Cohen-Stavi, Morton Leibowitz, Moshe B Hoshen, Shepherd R Singer, Haim Bitterman, Nicky Lieberman, Ran D Balicer
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108145 (2014)
AIMS: This study assesses the attributable impact of adherence to oral glucose medications as a risk factor for poor glycemic control in population subgroups of a large general population, using an objective medication adherence measure. METHODS: Usi
Externí odkaz:
https://doaj.org/article/c4bd2e954cf8454fbe222a28f22bfd85
Autor:
Idit Lavi, Devy Zisman, Adi Kibari, Guy Shalom, Tal Gazitt, Haim Bitterman, Sari Greenberg-Dotan, Ilan Feldhamer, Arnon D. Cohen
Publikováno v:
Clinical Rheumatology. 38:2069-2075
To assess the prevalence of risk factors associated with cardiovascular disease (CVD) and CVD-related morbidity in a large Middle-Eastern psoriatic arthritis (PsA) cohort. A retrospective case control study was conducted using Israel’s largest heal
Autor:
Lihi Eder, Sarit Nissan, Devy Zisman, Joy Feld, Michal A. Rahat, Haim Bitterman, Arie Laor, Doron Rimar, Muna Elias
Publikováno v:
JCR: Journal of Clinical Rheumatology. 24:302-307
The aims of this study were to evaluate the prevalence of metabolic syndrome (MetS) in psoriatic arthritis (PsA) patients according to the most recent definition in a Mediterranean population and to determine its association with biomarkers of inflam
Autor:
Sari Greenberg-Dotan, Idit Lavi, Arnon D. Cohen, Ilan Feldhamer, Ron Ilan Ashkenazi, Irina Bergman, Haim Bitterman, Devy Zisman, Amir Haddad, Erez Batat
Publikováno v:
The Journal of Rheumatology. 44:786-790
Objective.To investigate endocrine comorbidities in patients with psoriatic arthritis (PsA).Methods.A retrospective, cross-sectional study was performed with the database of Clalit Health Services, the largest healthcare provider in Israel, between 2
Autor:
Sivan Shohat-Spitzer, Haim Bitterman, Orit Jacobson, Chandra J Cohen-Stavi, Calanit Kay, Nicky Lieberman, Efrat Shadmi, Moshe Hoshen, Ran D. Balicer
Publikováno v:
Health Services Research. 50:1891-1909
Objective To assess a quality improvement disparity reduction intervention and its sustainability. Data Sources/Study Setting Electronic health records and Quality Index database of Clalit Health Services in Israel (2008–2012). Study Design Interru
Autor:
Efrat Shadmi, Moshe Hoshen, Ran D. Balicer, Haim Bitterman, Natalie Flaks-Manov, Orit Goldman
Publikováno v:
Medical Care. 53:283-289
Readmission prevention should begin as early as possible during the index admission. Early identification may help target patients for within-hospital readmission prevention interventions.To develop and validate a 30-day readmission prediction model
Autor:
Haim Bitterman, Dennis Linder, Doron Comaneshter, Alexandra Nathan, Nancy Agmon-Levin, Arnon D. Cohen, Guy Shalom
Publikováno v:
Journal of Investigative Dermatology. 135:3187-3189
Publikováno v:
The Cochrane Library
Background Venous thromboembolism (VTE) is a prevalent and serious condition. Its medical treatment requires anticoagulation, usually with either unfractionated or low molecular weight heparin (LMWH). Administration of unfractionated heparin (UFH) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::498fda796ce0880d62398ec0e8457788
https://eprints.whiterose.ac.uk/145622/1/Robertson_et_al_2017_Cochrane_Database_of_Systematic_Reviews_2_.pdf
https://eprints.whiterose.ac.uk/145622/1/Robertson_et_al_2017_Cochrane_Database_of_Systematic_Reviews_2_.pdf
Autor:
Ariel Hammerman, Haim Bitterman, Erez Battat, Sari Greenberg-Dotan, Ilan Feldhamer, Baruch Brenner
Publikováno v:
Acta Oncologica. 54:164-170
After a decade of extensive use, the actual contribution of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC) is still unclear.To evaluate 'real-life' outcomes of patients with mCRC before and after the introduction of bevaci